INNATE PHARMA reports a Return on Equity (ROE) of 466.96%.

What is IPHA's dividend yield?

INNATE PHARMA offers a dividend yield of 0.00%.

What is IPHA's Deepscope Quality Score?

Deepscope rates IPHA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IPHA?

Deepscope's AI Timing Score for IPHA is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IPHA belong to?

INNATE PHARMA is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

Cổ phiếu IPHA (NASDAQ) | INNATE PHARMA

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-10 | FS: 2026-03-31)

IPHA

INNATE PHARMA

US:NASDAQ STOCK Healthcare >> Biotechnology News 84

USD 1.75

-0.02 (-1.13%) Day Change

Watchlist Portfolio Compare Chart

-0.41

D/E

467.0%

ROE

-161.6%

ROA

0.00%

Div Yield

INNATE PHARMA
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.75 Price -0.02 (-1.13%) Day Change	NEWS SCORE: 84

IPHA Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) nhưng Thời điểm mua ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	84
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.75
PBV / Sector	-7.66 / 4.79
Earning Per Share	-1.07

PE / Sector	N/A / 17.89
PEG or PE/Growth / Sector	N/A / 0.56
Average 1M Daily Value	0.33 M GREAT
Average 1W Daily Value	0.01 M GREAT

Yếu tố Kỹ thuật

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-10,232.82 / 468.85
NPM Average (%) / Sector	-2,500.93 / -1,531.69
NPM Change Average (%) / Sector	833.00 / 5,028.65 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-161.59 / 31.69
ROA Average (%) / Sector	-63.37 / -353.18
ROA Change Average (%) / Sector	257.11 / 5,214.65 GREAT
ROE (%) / Sector	466.96 / 10.58 GREAT
ROE Average (%) / Sector	2.35 / 27.64
ROE Change Average (%) / Sector	904.65 / 2,048.88 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.77

Chi tiết đăng ký

Analyze Date	2026-06-11 09:55:10
Symbol	IPHA
Name	INNATE PHARMA
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	93.90 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	166.21 / 8,963.32

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 117, Avenue de Luminy, Marseille, France, 13009

Phone: 33 4 30 30 30 30

Website: https://www.innate-pharma.com

Employees: 164

Sector: Healthcare >> Biotechnology

Description: Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.